Literature DB >> 21460244

3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice.

Kazuhiko Ikeda1, Philip J Mason, Monica Bessler.   

Abstract

Overexpression of high mobility group AT-hook 2 (HMGA2) is found in a number of benign and malignant tumors, including the clonal PIGA(-) cells in 2 cases of paroxysmal nocturnal hemoglobinuria (PNH) and some myeloproliferative neoplasms (MPNs), and recently in hematopoietic cell clones resulting from gene therapy procedures. In nearly all these cases overexpression is because of deletions or translocations that remove the 3' untranslated region (UTR) which contains binding sites for the regulatory micro RNA let-7. We were therefore interested in the effect of HMGA2 overexpression in hematopoietic tissues in transgenic miceHmga2 mice) carrying a 3'UTR-truncated Hmga2 cDNA. ΔHmga2 mice expressed increased levels of HMGA2 protein in various tissues including hematopoietic cells and showed proliferative hematopoiesis with increased numbers in all lineages of peripheral blood cells, hypercellular bone marrow (BM), splenomegaly with extramedullary erythropoiesis and erythropoietin-independent erythroid colony formation. ΔHmga2-derived BM cells had a growth advantage over wild-type cells in competitive repopulation and serial transplantation experiments. Thus overexpression of HMGA2 leads to proliferative hematopoiesis with clonal expansion at the stem cell and progenitor levels and may account for the clonal expansion in PNH and MPNs and in gene therapy patients after vector insertion disrupts the HMGA2 locus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21460244      PMCID: PMC3112035          DOI: 10.1182/blood-2011-02-334425

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion.

Authors:  V Rosti; G Tremml; V Soares; P P Pandolfi; L Luzzatto; M Bessler
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies.

Authors:  M D Odero; F H Grand; S Iqbal; F Ross; J P Roman; J L Vizmanos; J Andrieux; J L Laï; M J Calasanz; N C P Cross
Journal:  Leukemia       Date:  2005-02       Impact factor: 11.528

3.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

7.  The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis.

Authors:  S Battista; V Fidanza; M Fedele; A J Klein-Szanto; E Outwater; H Brunner; M Santoro; C M Croce; A Fusco
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

8.  Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C.

Authors:  X Zhou; K F Benson; H R Ashar; K Chada
Journal:  Nature       Date:  1995-08-31       Impact factor: 49.962

9.  Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria.

Authors:  K Kawagoe; D Kitamura; M Okabe; I Taniuchi; M Ikawa; T Watanabe; T Kinoshita; J Takeda
Journal:  Blood       Date:  1996-05-01       Impact factor: 22.113

10.  bcl-x prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation.

Authors:  N Motoyama; T Kimura; T Takahashi; T Watanabe; T Nakano
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  54 in total

Review 1.  Hematopoietic stem cell engineering at a crossroads.

Authors:  Isabelle Rivière; Cynthia E Dunbar; Michel Sadelain
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

Review 2.  The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

Authors:  Tait H Huso; Linda M S Resar
Journal:  Expert Opin Ther Targets       Date:  2014-03-31       Impact factor: 6.902

Review 3.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

4.  A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development.

Authors:  Marcella Cesana; Michael H Guo; Davide Cacchiarelli; Lara Wahlster; Jessica Barragan; Sergei Doulatov; Linda T Vo; Beatrice Salvatori; Cole Trapnell; Kendell Clement; Patrick Cahan; Kaloyan M Tsanov; Patricia M Sousa; Barbara Tazon-Vega; Adriano Bolondi; Federico M Giorgi; Andrea Califano; John L Rinn; Alexander Meissner; Joel N Hirschhorn; George Q Daley
Journal:  Cell Stem Cell       Date:  2018-04-05       Impact factor: 24.633

5.  High mobility group protein-mediated transcription requires DNA damage marker γ-H2AX.

Authors:  Indrabahadur Singh; Nihan Ozturk; Julio Cordero; Aditi Mehta; Diya Hasan; Claudia Cosentino; Carlos Sebastian; Marcus Krüger; Mario Looso; Gianni Carraro; Saverio Bellusci; Werner Seeger; Thomas Braun; Raul Mostoslavsky; Guillermo Barreto
Journal:  Cell Res       Date:  2015-06-05       Impact factor: 25.617

6.  Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia.

Authors:  Dirk Heckl; Adrian Schwarzer; Reinhard Haemmerle; Doris Steinemann; Cornelia Rudolph; Britta Skawran; Sabine Knoess; Johanna Krause; Zhixiong Li; Brigitte Schlegelberger; Christopher Baum; Ute Modlich
Journal:  Mol Ther       Date:  2012-04-03       Impact factor: 11.454

7.  Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms.

Authors:  Koki Ueda; Kazuhiko Ikeda; Takayuki Ikezoe; Kayo Harada-Shirado; Kazuei Ogawa; Yuko Hashimoto; Takahiro Sano; Hiroshi Ohkawara; Satoshi Kimura; Akiko Shichishima-Nakamura; Yuichi Nakamura; Yayoi Shikama; Tsutomu Mori; Philip J Mason; Monica Bessler; Soji Morishita; Norio Komatsu; Kotaro Shide; Kazuya Shimoda; Shuhei Koide; Kazumasa Aoyama; Motohiko Oshima; Atsushi Iwama; Yasuchika Takeishi
Journal:  Blood Adv       Date:  2017-06-14

Review 8.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

9.  Effect of silencing of high mobility group A2 gene on gastric cancer MKN-45 cells.

Authors:  Chun-Hui Wei; Li-Xiu Wei; Ming-Yu Lai; Jia-Zhuang Chen; Xi-Jing Mo
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

Review 10.  Gene therapy for hemoglobinopathies: progress and challenges.

Authors:  Alisa Dong; Stefano Rivella; Laura Breda
Journal:  Transl Res       Date:  2013-01-19       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.